Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 16/20 | 0.63 |
| ▸ | GABRG2 | P18507 | 16/20 | 0.63 |
| ▸ | GABRB3 | P28472 | 16/20 | 0.63 |
| ▸ | GABRA5 | P31644 | 16/20 | 0.63 |
| ▸ | GABRA3 | P34903 | 16/20 | 0.63 |
| ▸ | GABRA2 | P47869 | 15/20 | 0.63 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.58 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.58 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21362836 | 0.94 | GABRA1 (0.64) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21362462 | 0.90 | GABRA1 (0.62) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21362801 | 0.86 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21362579 | 0.85 | GABRA1 (0.58) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL29941541 | 0.82 | GABRA1 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL22879653 | 0.82 | GABRA1 (0.60) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21362828 | 0.82 | GABRA1 (0.58) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30338442 | 0.82 | GABRA1 (0.58) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL29927474 | 0.81 | GABRA1 (0.54) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL21362470 | 0.81 | GABRA1 (0.57) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009598-A1 | PHTHALAZINE ISOXAZOLE ALKOXY DERIVATIVES, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai SIMRD Biotechnology Co., Ltd (CN) | 2021-01-14 | — | — | US | disclosed |
| WO-2019174577-A1 | PHTHALAZINE ISOXAZOLE ALKOXY DERIVATIVES, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009598-A1 | PHTHALAZINE ISOXAZOLE ALKOXY DERIVATIVES, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GABRA5, CYP3A5, GABRA4 | GABRA1 6/4885GABRG2 17/4885GABRB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.